WO2001078774A3 - Recombinant intracellular pathogen vaccines and methods for use - Google Patents

Recombinant intracellular pathogen vaccines and methods for use Download PDF

Info

Publication number
WO2001078774A3
WO2001078774A3 PCT/US2001/012380 US0112380W WO0178774A3 WO 2001078774 A3 WO2001078774 A3 WO 2001078774A3 US 0112380 W US0112380 W US 0112380W WO 0178774 A3 WO0178774 A3 WO 0178774A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
recombinant
methods
immunotherapeutics
intracellular
Prior art date
Application number
PCT/US2001/012380
Other languages
French (fr)
Other versions
WO2001078774A2 (en
Inventor
Marcus A Horwitz
Gunter Harth
Original Assignee
Univ California
Marcus A Horwitz
Gunter Harth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Marcus A Horwitz, Gunter Harth filed Critical Univ California
Priority to DE60135318T priority Critical patent/DE60135318D1/en
Priority to AU5355801A priority patent/AU5355801A/en
Priority to CN018110045A priority patent/CN1437479B/en
Priority to JP2001576073A priority patent/JP4868682B2/en
Priority to EP01927074A priority patent/EP1274453B1/en
Priority to CA2406225A priority patent/CA2406225C/en
Publication of WO2001078774A2 publication Critical patent/WO2001078774A2/en
Publication of WO2001078774A3 publication Critical patent/WO2001078774A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vaccines and immunotherapeutics for preventing intracellular pathogen diseases in mammals are provided that consist of recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same r other intracellular pathogens. Exemplary vaccines and immunotherapeutics include attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacterial and/or other intracellular pathogens. These exemplary vaccines are shown to produce surprisingly potent protective immune response in mammals that surpass those of any previously known anti-mycobacterium vaccine. More specifically, a recombinant BCG expressing the 30 kDa major extracellular non-fusion protein of Mycobacterium tubercolosis is provided. Additionally, methods for preventing and treating diseases caused by intracellular pathogens are provided. The methods of treating and preventing intracellular pathogen diseases utilize the described surprisingly efficacious vaccines and immunotherapeutics.
PCT/US2001/012380 2000-04-17 2001-04-16 Recombinant intracellular pathogen vaccines and methods for use WO2001078774A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60135318T DE60135318D1 (en) 2000-04-17 2001-04-16 RECOMBINANT BCG VACCINES AGAINST INTRA CELLULAR PATHOGENIC AND METHOD OF USE
AU5355801A AU5355801A (en) 2000-04-17 2001-04-16 Recombinant intracellular pathogen vaccines and methods for use
CN018110045A CN1437479B (en) 2000-04-17 2001-04-16 Recombinant intracellular pathogen vaccines and methods for use
JP2001576073A JP4868682B2 (en) 2000-04-17 2001-04-16 Recombinant intracellular pathogen vaccine and methods for use
EP01927074A EP1274453B1 (en) 2000-04-17 2001-04-16 Recombinant bcg vaccines against intracellular pathogens and methods for use
CA2406225A CA2406225C (en) 2000-04-17 2001-04-16 Recombinant intracellular pathogen vaccines and methods for use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/550,468 US6471967B1 (en) 2000-04-17 2000-04-17 Recombinant intracellular pathogen vaccines and methods for use
US09/550,468 2000-04-17

Publications (2)

Publication Number Publication Date
WO2001078774A2 WO2001078774A2 (en) 2001-10-25
WO2001078774A3 true WO2001078774A3 (en) 2002-03-28

Family

ID=24197308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012380 WO2001078774A2 (en) 2000-04-17 2001-04-16 Recombinant intracellular pathogen vaccines and methods for use

Country Status (12)

Country Link
US (1) US6471967B1 (en)
EP (1) EP1274453B1 (en)
JP (1) JP4868682B2 (en)
CN (1) CN1437479B (en)
AT (1) ATE404218T1 (en)
AU (1) AU5355801A (en)
CA (1) CA2406225C (en)
DE (1) DE60135318D1 (en)
ES (1) ES2315281T3 (en)
RU (1) RU2266132C2 (en)
WO (1) WO2001078774A2 (en)
ZA (1) ZA200209304B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300660B2 (en) * 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US7611720B2 (en) 2002-04-16 2009-11-03 Jun Liu Tuberculosis vaccines including recombinant BCG strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
DK2206514T3 (en) 2003-10-16 2014-04-22 Univ California Recombinant intracellular pathogenic immunogenic compositions and methods of use
US8287879B2 (en) 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
DK1827504T3 (en) * 2004-12-01 2011-08-29 Aeras Global Tb Vaccine Foundation Recombinant BCG strains with increased ability to escape from the endosome
GB0709373D0 (en) * 2007-05-16 2007-06-27 Thrombosis Res Inst BCG-based anti-atheroma vaccine
DK2341928T3 (en) * 2008-10-20 2015-09-28 Univ Zürich MYCOBACTERIUM TUBERCULOSIS VACCINE
WO2011159814A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
CN108434448A (en) * 2010-12-21 2018-08-24 马克斯·普朗克科学促进学会 Recombinant mycobacterium as vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
JP2903414B2 (en) 1989-05-31 1999-06-07 味の素株式会社 Acid-fast bacterium secretion expression vector and acid-fast bacterium
WO1993007897A1 (en) 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5736367A (en) 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US5679515A (en) 1994-10-03 1997-10-21 Pathogenesis Corporation Mycobacterial reporter strains and uses thereof
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
US5869057A (en) 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006626A1 (en) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARTH GUNTER ET AL: "High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets.", INFECTION AND IMMUNITY, vol. 65, no. 6, 1997, pages 2321 - 2328, XP002185377, ISSN: 0019-9567 *
HORWITZ MARCUS A ET AL: "Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 25, 5 December 2000 (2000-12-05), December 5, 2000, pages 13853 - 13858, XP002185379, ISSN: 0027-8424 *
LEE BAI-YU ET AL: "T-Cell epitope mapping of the three most abundant extracellular proteins of Mycobacterium tuberculosis in outbred guinea pigs.", INFECTION AND IMMUNITY, vol. 67, no. 5, May 1999 (1999-05-01), pages 2665 - 2670, XP002168051, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
JP4868682B2 (en) 2012-02-01
ATE404218T1 (en) 2008-08-15
ES2315281T3 (en) 2009-04-01
AU5355801A (en) 2001-10-30
EP1274453A2 (en) 2003-01-15
RU2002130716A (en) 2004-03-27
RU2266132C2 (en) 2005-12-20
CN1437479B (en) 2012-12-05
US6471967B1 (en) 2002-10-29
DE60135318D1 (en) 2008-09-25
JP2004507453A (en) 2004-03-11
ZA200209304B (en) 2004-08-13
EP1274453B1 (en) 2008-08-13
CN1437479A (en) 2003-08-20
WO2001078774A2 (en) 2001-10-25
CA2406225A1 (en) 2001-10-25
CA2406225C (en) 2012-06-26

Similar Documents

Publication Publication Date Title
WO2006036550A3 (en) Listeria-based and llo-based vaccines
WO2006032472A3 (en) Immunogenic composition for use in vaccination against staphylococcei
WO2001078774A3 (en) Recombinant intracellular pathogen vaccines and methods for use
EP0330359A3 (en) Composition useful in the diagnosis and treating of hiv-1 infection
AR035586A1 (en) COMPOSITION OF VACCINE, EQUIPMENT, METHODS TO INCREASE THE IMMUNE RESPONSE, USE OF A DERIVATIVE OF 1H-IMIDAZO (4,5-C) QUINOLIN-4-AMINA IN THE MANUFACTURE OF A MEDICINAL PRODUCT, AND COMBINATION OF COMPONENTS FOR SEPARATE, SEQUENTIAL ADMINISTRATION OR CONCOMITANT FOR USE IN DNA VACCINATION
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2003028760A3 (en) Vaccine
WO2006041933A3 (en) Improved vaccines
JP2007308508A (en) Chlamydia vaccine
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
Bengoa-Luoni et al. The potential of a DIVA-like recombinant vaccine composed by rNcSAG1 and rAtHsp81. 2 against vertical transmission in a mouse model of congenital neosporosis
WO2003059385A3 (en) Hiv vaccine and method of use
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2005037222A3 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
Antonoglou et al. Heterologous chimeric construct comprising a modified bacterial superantigen and a cruzipain domain confers protection against Trypanosoma cruzi infection
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2004031356A3 (en) Recombinant intracellular pathogen immunogenic compositions and methods for use
WO1997047271A3 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
Pirdel et al. Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB/c mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2406225

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 576073

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001927074

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/1299/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001253558

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002/09304

Country of ref document: ZA

Ref document number: 200209304

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2002 2002130716

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 018110045

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001927074

Country of ref document: EP